Biopharma | January 01, 2026
Savara resubmits FDA application for potential treatment in rare lung disease patients
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Applications include detailed scientific rationale and supporting clinical evidence
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The study met its primary endpoint with flying colors
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Harbour BioMed brings advanced antibody discovery platforms to the table
Subscribe To Our Newsletter & Stay Updated
